A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells

Virology

Volumn 419, Issue 2, 2011, Pages 117-125

  Mourez, Thomas ^a,b,c   Mesel Lemoine, Mariana ^a   Combredet, Chantal ^a   Najburg, Valérie ^a   Cayet, Nadège ^a   Tangy, Frédéric ^a  

^a INSTITUT PASTEUR   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chimera; HIV; Measles; SIV; Vaccine

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ARTICLE; CCR5+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD46+ T LYMPHOCYTE; CELL AGGREGATION; CELL SIZE; CHIMERA; CLONE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HUMAN; HUMAN CELL; LENTIVIRINAE; LYMPHOCYTE COUNT; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SYNCYTIUM; T LYMPHOCYTE; TARGET CELL; VACCINE PRODUCTION; VIRAL GENETICS; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CERCOPITHECUS AETHIOPS; FLUORESCENT ANTIBODY TECHNIQUE; GENE PRODUCTS, ENV; GIANT CELLS; HEMAGGLUTININS, VIRAL; HUMANS; MACACA MULATTA; MEASLES VIRUS; RECEPTORS, CCR5; RECOMBINANT FUSION PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

MEASLES VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 80052935764     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.08.007     Document Type: Article

References (48)

1. Abrahamyan L.G., Mkrtchyan S.R., Binley J., Lu M., Melikyan G.B., Cohen F.S. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J. Virol. 2005, 79(1):106-115.
2. Bomsel M., Tudor D., Drillet A.S., Alfsen A., Ganor Y., Roger M.G., Mouz N., Amacker M., Chalifour A., Diomede L., Devillier G., Cong Z., Wei Q., Gao H., Qin C., Yang G.B., Zurbriggen R., Lopalco L., Fleury S. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34(2):269-280.
3. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., McElrath M.J., Casimiro D.R., Gottesdiener K.M., Chodakewitz J.A., Corey L., Robertson M.N. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
4. Bultmann A., Muranyi W., Seed B., Haas J. Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression. J. Virol. 2001, 75(11):5263-5276.
5. Calain P., Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 1993, 67(8):4822-4830.
6. Combredet C., Labrousse-Najburg V., Mollet L., Lorin C., Delebecque F., Hurtrel B., McClure H., Feinberg M., Brahic M., Tangy F. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J. Virol. 2003, 77(21):11546-11554.
7. de Swart R.L. The pathogenesis of measles revisited. Pediatr. Infect. Dis. J. 2008, 27(10 Suppl.):S84-S88.
8. Desprès P., Combredet C., Frenkiel M., Lorin C., Brahic M., Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J. Infect. Dis. 2005, 191(2):207-214.
9. Dhiman N., Jacobson R.M., Poland G.A. Measles virus receptors: SLAM and CD46. Rev. Med. Virol. 2004, 14(4):217-229.
10. Dorig R.E., Marcil A., Chopra A., Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993, 75(2):295-305.
11. Ferre A.L., Hunt P.W., Critchfield J.W., Young D.H., Morris M.M., Garcia J.C., Pollard R.B., Yee H.F., Martin J.N., Deeks S.G., Shacklett B.L. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113(17):3978-3989.
12. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191(5):654-665.
13. Foley H.D., Otero M., Orenstein J.M., Pomerantz R.J., Schnell M.J. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J. Virol. 2002, 76(1):19-31.
14. Guerbois M., Moris A., Combredet C., Najburg V., Ruffie C., Fevrier M., Cayet N., Brandler S., Schwartz O., Tangy F. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 2009, 388(1):191-203.
15. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., Lang J., Ocran S., Mitchell F., Parsons M., Brown N., Brandler S., Fournier C., Barrere B., Rizvi F., Travassos A., Nichols R., Trent D., Monath T. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 2004, 78(9):4761-4775.
16. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
17. Kobune F., Sakata H., Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J. Virol. 1990, 64(2):700-705.
18. Lemon K., de Vries R.D., Mesman A.W., McQuaid S., van Amerongen G., Yuksel S., Ludlow M., Rennick L.J., Kuiken T., Rima B.K., Geijtenbeek T.B., Osterhaus A.D., Duprex W.P., de Swart R.L. Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog. 2011, 7(1):e1001263.
19. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 2006, 6(12):930-939.
20. Liniger M., Zuniga A., Morin T.N., Combardiere B., Marty R., Wiegand M., Ilter O., Knuchel M., Naim H.Y. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 2009, 27(25-26):3299-3305.
21. Lorin C., Mollet L., Delebecque F., Combredet C., Charneau P., Hurtrel B., Brahic M., Tangy F. A single injection of recombinant measles vaccines expressing HIV-1 Clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 2004, 78(1):146-157.
22. Lorin C., Delebecque F., Labrousse V., Da Silva L., Lemonnier F., Brahic M., Tangy F. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV 1 conserved epitopes. Vaccine 2005, 23(36):4463-4472.
23. Lorin C., Saidi H., Belaid A., Zairi A., Baleux F., Hocini H., Belec L., Hani K., Tangy F. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology 2005, 334(2):264-275.
24. Malkevitch N.V., Robert-Guroff M. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev. Vaccines 2004, 3(4 Suppl.):S105-S117.
25. Marechal V., Clavel F., Heard J.M., Schwartz O. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J. Virol. 1998, 72(3):2208-2212.
26. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
27. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., Casimiro D.R. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905.
28. Montefiori D.C., Mascola J.R. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?. Curr. Opin. HIV AIDS 2009, 4(5):347-351.
29. Mrkic B., Pavlovic J., Rulicke T., Volpe P., Buchholz C.J., Hourcade D., Atkinson J.P., Aguzzi A., Cattaneo R. Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 1998, 72(9):7420-7427.
30. Mrkic B., Odermatt B., Klein M., Billeter M., Pavlovic J., Cattaneo R. Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J. Virol. 1999, 74(3):1364-1372.
31. Naniche D., Varior-Krishnan G., Cervoni F., Wild T.F., Rossi B., Rabourdin-Combe C., Gerlier D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 1993, 67(10):6025-6032.
32. Parks C.L., Lerch R.A., Walpita P., Sidhu M.S., Udem S.A. Enhanced measles virus cDNA rescue and gene expression after heat shock. J. Virol. 1999, 73(5):3560-3566.
33. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194(12):1661-1671.
34. Pope M., Haase A.T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat. Med. 2003, 9(7):847-852.
35. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 2009, 9(10):741-747.
36. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., Pirani A., Gernert K., Deng J., Marzolf B., Kennedy K., Wu H., Bennouna S., Oluoch H., Miller J., Vencio R.Z., Mulligan M., Aderem A., Ahmed R., Pulendran B. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2009, 10(1):116-125.
37. Radecke F., Spielhofer P., Schneider H., Kaelin K., Huber M., Dotsch C., Christiansen G., Billeter M.A. Rescue of measles viruses from cloned DNA. EMBO J. 1995, 14(23):5773-5784.
38. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361(23):2209-2220.
39. Rouxel R.N., Svitek N., von Messling V. A chimeric measles virus with canine distemper envelope protects ferrets from lethal distemper challenge. Vaccine 2009, 27(36):4961-4966.
40. Salter R.D., Howell D.N., Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985, 21(3):235-246.
41. Sellin C.I., Davoust N., Guillaume V., Baas D., Belin M.F., Buckland R., Wild T.F., Horvat B. High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice. J. Virol. 2006, 80(13):6420-6429.
42. Singh M., Cattaneo R., Billeter M.A. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J. Virol. 1999, 73(6):4823-4828.
43. Spielhofer P., Bachi T., Fehr T., Christiansen G., Cattaneo R., Kaelin K., Billeter M., Naim H. Chimeric measles viruses with a foreign envelope. J. Virol. 1998, 72:2150-2159.
44. Tangy, F., Charneau, P., Jacob, Y., 2006. Cells and methodology to generate non-segmented negative-strand RNA viruses. European Patent Application filed on August 25, 2006 N° 06291358.7.
45. Tatsuo H., Ono N., Tanaka K., Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000, 406(6798):893-897.
46. Wang Z., Hangartner T., Cornu L., Martin A., Zuniga M., Billeter M., Naim H. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 2001, 19:2329-2336.
47. Welstead G.G., Iorio C., Draker R., Bayani J., Squire J., Vongpunsawad S., Cattaneo R., Richardson C.D. Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(45):16415-16420.
48. Yanagi Y., Takeda M., Ohno S. Measles virus: cellular receptors, tropism and pathogenesis. J. Gen. Virol. 2006, 87(Pt 10):2767-2779.